Clinical Trial Detail

NCT ID NCT02964078
Title Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

kidney cancer

Therapies

Aldesleukin + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.